









































- Simulations. Evidence-based complementary and alternative medicine : eCAM, 2018, 1943203.  
<https://doi.org/10.1155/2018/1943203>
- Gaddam, A., Galla, C., Thummisetti, S., Marikanty, R., Palanisamy, U., & Rao, P. (2015, October 2). Role of Fenugreek in the prevention of type 2 diabetes mellitus IN prediabetes. Retrieved April 28, 2021
- Al-Timimi, L. (2019, December 1). Antibacterial and anticancer activities of fenugreek seed extract. Retrieved April 28, 2021
- Saxena, B., Saxena, U.. (2009, January). Anti-hyperlipidemic activity of fenugreek (*Trigonella foenum-graecum*) seeds extract in triton and high fat diet induced hyperlipidemic model: A potent anti-atherosclerotic agent. *Pharmacologyonline*. 2. 616-624. Retrieved May 8, 2021
- Habib-Martin, Z., Hammad, H., Afifi, F., Zihlif, M., Al-Ameer, H., Saleh, M., . . . Nassar, Z. (2017, August 03). In vitro and in vivo evaluation of the antiangiogenic activities of trigonella foenum-graecum extracts. Retrieved April 28, 2021
- Taj Eldin, I., Abdalmutalab, M., & Bikir, H. (2013). An in VITRO anticoagulant effect Of fenugreek (*Trigonella foenum-graecum*) in blood samples of NORMAL Sudanese individuals. Retrieved April 28, 2021
- Jesus, M., Martins, A., Gallardo, E., & Silvestre, S. (2016). Diosgenin: Recent highlights on pharmacology and analytical methodology. Retrieved April 28, 2021
- Ahmed M.A. Abd-El M., Husam O. (2011). Elicitation of Trigonelline and 4-Hydroxyisoleucine with Hypoglycemic Activity in Cell Suspension Cultures of *Trigonella foenum graecum* L. *The Open Conference Proceedings Journal*. Retrieved May 8, 2021
- Garg, R. (2016, February 19). Fenugreek: Multiple health benefits. Retrieved April 28, 2021
- Mansour, E., & El-Adawy, T. (2002, May 25). Nutritional potential and functional properties of heat-treated and germinated fenugreek seeds. Retrieved April 28, 2021
- Worldwide toll of diabetes. (2019). International Diabetes Federation.  
<https://www.diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html#:~:text=Today%2C%20we%20calculate%20that%209.3,in%202025%20was%20438%20million.>
- Baquer, N.Z., Kumar, P., Taha, A. et al. Metabolic and molecular action of *Trigonella foenum-graecum* (fenugreek) and trace metals in experimental diabetic tissues. *J Biosci* 36, 383–396 (2011).
- Jl., P. M. V. M. (n.d.). *The metabolic syndrome: definition, global impact, and pathophysiology*. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
- The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Ozougwu, J. C., Obimba, K. C., Belonwu, C. D., and Unakalamba, C. B. JPAP 2017, DOI: 10.5897/JPAP2013.0001
- Diabetes 2030: insights from yesterday, today, and future trends. Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. *Popul Health Manag*. 2017;20:6–12
- Habtemariam, S. “Chapter 17 - The chemical and pharmacological basis of fenugreek (*Trigonella foenum-graecum* L.) as potential therapy for type 2 diabetes and associated diseases.” *Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases- The Chemical and Pharmacological Basis of their Action*, 2019, p. 579-637
- Kumar, S., Narwal, S., Kumar, V., & Prakash, O. (2011, January). A-Glucosidase inhibitors from plants: A natural approach to treat diabetes. Retrieved April 28, 2021
- Agarwal, P., Gupta, R. (September 2016). Alpha-amylase inhibition can treat diabetes mellitus. *Journal of Medical Physics*. 5(4). Retrieved May 8, 2021
- Ghosh, S., More, P., Derle, A., Patil, A., Markad, P., Asok, A., . . . Chopade, B. (n.d.). Diosgenin from *Dioscorea Bulbifera*: NOVEL hit for treatment of Type II diabetes Mellitus with inhibitory activity AGAINST  $\alpha$ -Amylase And  $\alpha$ -glucosidase. Retrieved April 28, 2021
- Jemal, K. (2019, January 01). Molecular docking studies of PHYTOCHEMICALS of *allophylus serratus* Against cyclooxygenase-2 enzyme. Retrieved April 28, 2021

- National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 5570, Trigonelline. Retrieved May 7, 2021
- National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 99474, Diosgenin. Retrieved May 7, 2021
- National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 5962, Lysine. Retrieved May 7, 2021
- National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 6106, Leucine. Retrieved May 7, 2021
- National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 2773624, 4-Hydroxyisoleucine. Retrieved May 7, 2021
- H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, P.E. Bourne. (2000) The Protein Data Bank Nucleic Acids Research, 28: 235-242.
- Wang, F., Wu, F., Li, C., Jia, C., Su, S., Hao, G., & Yang, G. (2019, November 27). Acid: A free tool for drug repurposing using consensus inverse docking strategy. Retrieved April 28, 2021
- O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, Journal of Computational Chemistry 31 (2010) 455-461 DOI 10.1002/jcc.21334
- Ref. Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, San Diego: Dassault Systèmes, 2016.
- The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.
- Roskoski R., Jr (2019). Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological research, 142, 151–168. <https://doi.org/10.1016/j.phrs.2019.01.039>
- Wójcikowski, J., Danek, P. J., Basińska-Ziobroń, A., Pukło, R., & Daniel, W. A. (2020, March 26). *In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug–drug interactions*. Pharmacological Reports.
- Stanford, S. M., Aleshin, A. E., Zhang, V., Ardecky, R. J., Hedrick, M. P., Zou, J., ... Bottini, N. (2017, March 27). *Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase*. Nature News.
- Víteček, J., Lojek, A., Valacchi, G., & Kubala, L. (2012, September 4). *Arginine-Based Inhibitors of Nitric Oxide Synthase: Therapeutic Potential and Challenges*. Mediators of Inflammation.
- Sin N;Meng L;Wang MQ;Wen JJ;Bornmann WG;Crews CM; (n.d.). *The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2*. Proceedings of the National Academy of Sciences of the United States of America.
- Di Costanzo, L., Ilies, M., Thorn, K. J., & Christianson, D. W. (2010, April 15). *Inhibition of human arginase I by substrate and product analogues*. Archives of biochemistry and biophysics.
- Du, M., Yang, L., Gu, J., Wu, J., Ma, Y., & Wang, T. (2020, December 30). *Inhibition of Peptidyl Arginine Deiminase-4 Prevents Renal Ischemia-Reperfusion-Induced Remote Lung Injury*. Mediators of Inflammation.
- Stanford, S., Aleshin, A., Zhang, V., Ardecky, R., Hedrick, M., Zou, J., . . . Bottini, N. (2017, June). *Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase*. Retrieved April 28, 2021
- LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Chiarugi P, Cirri P, Marra F, Raugei G, Camici G, Manao G, Ramponi G Biochem Biophys Res Commun. 1997 Sep 18; 238(2):676-82.
- Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. Pandey SK, Yu XX, Watts LM, Michael MD, Sloop KW, Rivard AR, Leedom TA, Mancham VP, Samadzadeh L, McKay RA, Monia BP, Bhanot S J Biol Chem. 2007 May 11; 282(19):14291-9.
- LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Chiarugi P, Cirri P, Marra F, Raugei G, Camici G, Manao G, Ramponi G Biochem Biophys Res Commun. 1997 Sep 18; 238(2):676-82.
- Williams, I., McClatchey, P., Bracy, D., Valenzuela, F., & Wasserman, D. (2018, October 01). *Acute nitric oxide synthase inhibition accelerates transendothelial insulin efflux in vivo*. Retrieved April 28, 2021

- Proietto, J., Malloy, J., Zhuang, D., Arya, M., Cohen, N., Looze, F., . . . Kim, D. (2018, July 11). Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 DIABETES: A randomised, placebo-controlled clinical trial. Retrieved April 28, 2021
- Wong, S. L., & Wagner, D. D. (2018). Peptidylarginine deiminase 4: a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 32(12), fj201800691R. Advance online publication. <https://doi.org/10.1096/fj.201800691R>
- Wong, S. L., Demers, M., Martinod, K., Gallant, M., Wang, Y., Goldfine, A. B., Kahn, C. R., and Wagner, D. D. (2015) Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. *Nat. Med.* 21, 815–819
- Laakso, M., and Kuusisto, J. (2014) Insulin resistance and hyperglycaemia in cardiovascular disease development. *Nat. Rev. Endocrinol.* 10, 293–302
- Morel, O., Jesel, L., Abbas, M., and Morel, N. (2013) Prothrombotic changes in diabetes mellitus. *Semin. Thromb. Hemost.* 39, 477–488